healthevidencedigest

Tag: asthma

  • Your Asthma Is Still Not Controlled on Two Inhalers. The FDA Just Approved a Third Drug You Can Add Without Adding a Second Device.

    Your Asthma Is Still Not Controlled on Two Inhalers. The FDA Just Approved a Third Drug You Can Add Without Adding a Second Device.

    📌 The essentials On May 14, 2026, the FDA approved Trimbow (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate, Chiesi USA), a single-inhaler triple combination therapy for the long-term maintenance treatment of asthma in adults. It is the first and currently only inhaled triple combination therapy approved in the United States for asthma that delivers all three drug classes, an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), in a single pressurized metered-dose inhaler. Indication: long-term maintenance treatment of asthma in adults. Not for children. Not for use as a rescue inhaler. Dosing: 2 inhalations twice daily (morning and evening), 4 total per day. Two strengths: 86 mcg/4.9 mcg/10.6 mcg and 172 mcg/4.9 mcg/10.6 mcg per actuation. The clinical basis: two Phase 3 randomized, double-blind, active-controlled trials, TRIMARAN and TRIGGER, enrolling 2,592 adults with uncontrolled asthma. Both trials showed statistically significant improvements in pre-dose FEV1 at 26 weeks compared with dual ICS/LABA therapy alone. TRIMARAN also showed a statistically significant 15% reduction in the rate of moderate and severe exacerbations. Critical safety note: Trimbow contains a LABA (formoterol). Do not use any other LABA or any other anticholinergic medication while taking Trimbow.

    Asthma affects approximately 27 million Americans and is a leading cause of emergency department visits, missed school and work days, and chronic respiratory morbidity. For most patients, the treatment goal is straightforward: control inflammation with an inhaled corticosteroid, open the airways with a bronchodilator, and live without symptoms. For many, that goal is achievable with a combination ICS/LABA inhaler.

    But a substantial proportion of patients, estimated at 5 to 10% of all asthma patients and sometimes characterized as moderate to severe uncontrolled asthma, do not achieve adequate control on dual ICS/LABA therapy even with appropriate adherence and technique. For these patients, the next therapeutic step has typically involved adding a long-acting muscarinic antagonist (LAMA), a third drug class that relaxes airway smooth muscle through a different mechanism than beta-agonists. Until now, adding a LAMA meant adding a separate inhaler, which adds complexity, cost, and another opportunity for missed or incorrect doses.

    On May 14, 2026, the FDA approved Trimbow, a single inhaler containing all three classes simultaneously. The clinical data supporting it has been in the literature since 2019, published in The Lancet. The U.S. approval now makes this approach officially available to American patients and prescribers.

    What Uncontrolled Asthma on ICS/LABA Looks Like and Why a Third Drug Class Helps

    To understand what Trimbow adds, it helps to understand the three drug classes it combines and why each contributes something the others cannot fully replace.

    Beclomethasone dipropionate: the ICS component

    Beclomethasone dipropionate (BDP) is a synthetic glucocorticoid that suppresses the airway inflammation that underlies asthma. Inflammation is the root cause of the chronic bronchial hyperreactivity that makes asthmatic airways prone to spasm, swelling, and mucus production. ICS therapy is the foundational treatment for persistent asthma because no bronchodilator, however effective at opening airways acutely, addresses the underlying inflammatory state. BDP is one of the most extensively studied and commonly used ICS agents. In Trimbow, it is formulated in an extrafine particle size (mass median aerodynamic diameter below 2 micrometers) that allows improved deposition in the small airways, a region of the lung that is a significant site of inflammation in asthma and that larger-particle formulations reach less effectively.

    Formoterol fumarate: the LABA component

    Formoterol fumarate is a long-acting beta2-agonist (LABA) that works by binding to beta2-adrenergic receptors on airway smooth muscle, causing relaxation and dilation. This bronchodilation reduces airway resistance and improves airflow. Unlike short-acting beta2-agonists (SABAs) such as albuterol, which last 4 to 6 hours and are used for quick relief, formoterol is designed for sustained bronchodilation over approximately 12 hours. It is taken twice daily as a maintenance medication, not for acute symptoms. Formoterol also has a relatively rapid onset compared to other LABAs, beginning to act within minutes of inhalation.

    An important safety note: LABAs, when used without an ICS, increase the risk of asthma-related hospitalizations and death. This risk drove FDA requirements that LABAs only be prescribed in combination with ICS for asthma. Trimbow contains both, so this risk is not present in the way it is with LABA-only products.

    Glycopyrrolate: the LAMA component

    Glycopyrrolate (also called glycopyrronium) is a long-acting muscarinic antagonist (LAMA) that blocks muscarinic receptors on airway smooth muscle and submucosal glands. Muscarinic receptors respond to acetylcholine, a neurotransmitter released by the parasympathetic nervous system. Parasympathetic stimulation causes bronchoconstriction and increased mucus secretion, both of which worsen airway obstruction in asthma. Glycopyrrolate blocks these effects, producing additional bronchodilation and reducing mucus production through a mechanism completely distinct from formoterol’s beta-agonist pathway.

    This mechanistic complementarity is the rationale for combining a LABA and a LAMA: they dilate airways through two separate receptor pathways, producing additive bronchodilation beyond what either achieves alone. In COPD, where LABA/LAMA combinations are well-established, this additive effect is substantial. In asthma, the role of LAMA therapy is newer and the evidence base is still evolving, which is what makes the TRIMARAN and TRIGGER trial data important.

    Why adding a LAMA to asthma therapy is different from COPD In COPD, LAMA therapy is foundational and often used as first-line bronchodilation, because the disease is primarily driven by fixed airflow limitation and parasympathetically mediated bronchoconstriction. In asthma, the primary problem is ICS-reversible inflammation with episodic bronchospasm, and the role of the parasympathetic nervous system is less dominant than in COPD. This is why LAMAs were not part of asthma therapy for many years: the theoretical rationale was weaker. The TRIMARAN and TRIGGER trials were specifically designed to test whether adding a LAMA to ICS/LABA in patients already failing dual therapy would produce meaningful additional benefit. The answer, at least for lung function and for severe exacerbations in TRIMARAN, was yes. The question of which patients benefit most, and how much, is one the subgroup analyses have tried to answer.

    The TRIMARAN and TRIGGER Trials: What the Evidence Actually Shows

    The FDA approval is based on two Phase 3 randomized, double-blind, active-controlled trials, both published in The Lancet in November 2019 and extensively analyzed in subsequent publications.

    Trial design

    Both trials enrolled adults with uncontrolled asthma, defined as:

    • Asthma Control Questionnaire-7 (ACQ-7) score of 1.5 or higher (indicating inadequate asthma control)
    • Pre-bronchodilator FEV1 below 80% of predicted normal (confirming measurable airflow limitation)
    • History of at least one moderate or severe asthma exacerbation in the prior year (establishing meaningful disease burden)
    • Current treatment with medium-dose ICS/LABA (TRIMARAN) or high-dose ICS/LABA (TRIGGER)

    TRIMARAN NCT02676076: enrolled 1,155 patients. Compared medium-strength BDP/FF/G (100 mcg/6 mcg/10 mcg per actuation) versus medium-strength BDP/FF (100 mcg/6 mcg) for 52 weeks.

    TRIGGER NCT02676089: enrolled 1,437 patients. Compared high-strength BDP/FF/G (200 mcg/6 mcg/10 mcg) versus high-strength BDP/FF (200 mcg/6 mcg), with an additional open-label arm receiving high-strength BDP/FF plus tiotropium (a separate LAMA) once daily, providing a comparison against adding a LAMA in a separate inhaler rather than a combined one.

    Co-primary endpoints for both trials were pre-dose FEV1 at week 26 and the rate of moderate and severe exacerbations over 52 weeks.

    Primary endpoint results

    OutcomeTRIMARAN (medium dose)TRIGGER (high dose)
    Improvement in pre-dose FEV1 at Week 26 (BDP/FF/G vs BDP/FF)+57 mL (95% CI 15 to 99; p=0.0080)+73 mL (95% CI 26 to 120; p=0.0025)
    Rate of moderate-to-severe exacerbations over 52 weeks (rate ratio vs BDP/FF)Rate ratio 0.85 (95% CI 0.73 to 0.99; p=0.033), 15% reductionRate ratio 0.88 (95% CI 0.75 to 1.03; p=0.11), 12% reduction, not statistically significant
    Patients experiencing moderate-to-severe exacerbations58.6% (BDP/FF/G) vs 66.0% (BDP/FF)56.6% (BDP/FF/G) vs 63.7% (BDP/FF)
    Patients experiencing severe exacerbations18.2% (BDP/FF/G) vs 22.4% (BDP/FF)Numerically reduced; statistically significant for severe exacerbations
    Tiotropium add-on vs BDP/FF/G (TRIGGER only)—No statistically significant differences between the combined inhaler and the separate LAMA arm

    Source: Virchow JC et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER). The Lancet. 2019;394(10210):1737-1749. doi:10.1016/S0140-6736(19)32028-9.

    The FEV1 improvements in both trials are statistically significant and, while modest in absolute terms (57 to 73 mL), are consistent with meaningful clinical benefit in a population where gains are incremental. The 15% reduction in moderate and severe exacerbation rate in TRIMARAN is the more clinically impactful finding: exacerbations are the main driver of asthma-related hospitalizations, emergency visits, oral corticosteroid courses, and lung function decline over time. Reducing exacerbations reduces downstream harm.

    The fact that TRIGGER’s exacerbation reduction did not reach statistical significance (p=0.11 for combined moderate and severe) is worth acknowledging honestly. However, the point estimate was similar to TRIMARAN (12% vs 15%), and the severe exacerbation data in TRIGGER was statistically significant. The likely explanation for the differing statistical outcomes is that TRIGGER enrolled patients on higher-dose ICS/LABA, who are by definition more disease-refractory, making further improvement harder to demonstrate and more heterogeneous.

    The TRIGGER tiotropium add-on arm is also clinically important. The three-way comparison showed no statistically significant difference in outcomes between the triple combination inhaler and adding tiotropium as a separate inhaler to ICS/LABA. This means Trimbow is not demonstrably superior to the established approach of adding a separate LAMA inhaler. What it offers is the same clinical effect in a single device rather than two, which is a convenience and adherence advantage rather than a pharmacological superiority.

    Remission-on-treatment analysis

    A post-hoc analysis published in the Journal of Allergy and Clinical Immunology (2025) evaluated whether triple therapy increased the proportion of patients achieving on-treatment remission, defined as no severe exacerbations and no systemic corticosteroid use over 52 weeks, plus ACQ-5 score below 1.5 at weeks 26, 40, and 52, plus stable or improved lung function. In TRIMARAN, 30.2% of patients on triple therapy met all remission criteria compared with 25.6% on dual therapy. This finding is exploratory and post-hoc, but it provides useful context for the meaningful goal of deep disease control rather than simply symptom reduction.

    The Extrafine Formulation: Why Particle Size Matters

    Trimbow is specifically described as an extrafine formulation, meaning the active ingredients are delivered in particles with a mass median aerodynamic diameter below 2 micrometers. This is smaller than standard inhaled corticosteroid particles, which typically have diameters of 2 to 5 micrometers.

    The significance of small-particle size relates to where in the lung the drug deposits. Larger particles tend to deposit in the central airways, the larger bronchi visible on bronchoscopy. Smaller particles travel further into the lung, reaching the small airways below 2 mm in diameter. In asthma, inflammation and airflow limitation are present throughout the bronchial tree, including in these small peripheral airways, and conventional larger-particle inhalers may not adequately treat this compartment.

    This is not a theoretical claim for Trimbow specifically: the TRIMARAN and TRIGGER trials were conducted with the extrafine formulation, and the results reflect its performance. Whether the extrafine delivery is responsible for a meaningful component of the observed benefit, or whether standard-particle LABA/LAMA/ICS would perform similarly, has not been tested head-to-head in asthma.

    Who Is Trimbow For? Patient Selection and the Treatment Hierarchy

    Trimbow is not a first-line therapy for asthma. It is indicated for adults with asthma that is not adequately controlled on existing treatment, specifically on medium or high-dose ICS/LABA combination therapy. The GINA (Global Initiative for Asthma) guidelines position LAMA add-on as a Step 4 to 5 consideration for patients with persistent symptoms or exacerbations on medium-to-high-dose ICS/LABA, which is exactly the population studied in TRIMARAN and TRIGGER.

    Trimbow is appropriate to consider for patients who:

    • Have documented uncontrolled asthma (frequent symptoms, reliever use, recent exacerbations, or reduced quality of life) despite adherent use of a medium or high-dose ICS/LABA inhaler
    • Have experienced at least one moderate or severe exacerbation in the past year
    • Have pre-bronchodilator FEV1 below 80% of predicted, indicating measurable airflow limitation
    • Are adults (Trimbow is not approved for children)

    Trimbow is not appropriate for patients who:

    • Need emergency or acute symptom relief (Trimbow is a maintenance inhaler, not a rescue inhaler; always carry albuterol or another SABA)
    • Are already using a separate LAMA inhaler (tiotropium, ipratropium, aclidinium, umeclidinium) or another LABA (salmeterol, vilanterol, indacaterol, olodaterol) — combining Trimbow with these creates duplicate drug class exposure with elevated risk of cardiovascular and anticholinergic side effects
    • Are children under 18
    • Have poorly controlled narrow-angle glaucoma or significant urinary retention from enlarged prostate, as the anticholinergic component can worsen both

    Safety: What Patients and Clinicians Need to Know

    The safety profile of Trimbow reflects the combined profile of its three components, each of which has decades of clinical experience in other products.

    The LABA safety warning

    LABAs carry a class-level FDA warning: when used without an ICS, they increase the risk of asthma-related death and hospitalization. This risk is resolved when LABAs are combined with an ICS, as they are in Trimbow. The warning is present on the label but not a contraindication for ICS/LABA combination use. It is the reason that LABAs should never be used as monotherapy in asthma.

    Serious risks requiring awareness

    • Oral thrush (oropharyngeal candidiasis): The most common ICS-related complication. Rinse and gargle with water after every use, without swallowing. This simple step significantly reduces the risk.
    • Adrenal insufficiency: In patients transitioning from oral or systemic corticosteroids to an ICS-containing inhaler, the adrenal glands may not immediately produce sufficient cortisol during physiological stress (illness, surgery, trauma). This risk is real during the transition period and requires gradual steroid tapering under medical supervision.
    • Paradoxical bronchospasm: Occasionally, an inhaled medication causes immediate airway tightening rather than opening. If this occurs, stop Trimbow and seek medical care immediately.
    • Cardiovascular effects: The beta-agonist and anticholinergic components can increase heart rate and blood pressure. Monitor patients with underlying cardiovascular conditions.
    • Glaucoma and urinary retention: The anticholinergic component (glycopyrrolate) increases intraocular pressure and can worsen urinary retention from enlarged prostate. Patients with these conditions need evaluation before starting Trimbow, and regular eye exams are recommended during use.
    • Osteoporosis: Long-term ICS use at higher doses contributes to bone density reduction. Assess bone health, particularly in patients with other osteoporosis risk factors.
    • Metabolic effects: Elevated blood glucose (particularly in patients with diabetes or at risk for it) and low potassium are possible with LABA therapy.

    Common side effects

    Bronchitis, upper respiratory infections, hoarseness, mouth and throat discomfort, back pain, and muscle spasms were among the most commonly reported adverse events in clinical trials. Oral hoarseness specifically is related to vocal cord effects of the corticosteroid and can often be reduced by rinsing after use and using a spacer device.

    Dosing, Administration, and Storage

    FeatureDetails
    Dose2 inhalations twice daily (morning and evening), 4 total puffs per day
    Available strengths86 mcg/4.9 mcg/10.6 mcg (medium) and 172 mcg/4.9 mcg/10.6 mcg (high) per actuation
    Device typePressurized metered-dose inhaler (pMDI)
    Spacer useRecommended to improve lung deposition and reduce oropharyngeal deposition
    Rinse mouthAfter every use, with water, without swallowing
    Storage before first useRefrigerate at 36°F to 46°F (2°C to 8°C)
    Storage after first useBelow 77°F (25°C) for a maximum of 2 months; discard after 2 months or when dose counter reaches zero
    Do notFreeze; use near heat or open flame; pierce the canister
    Missed doseTake as soon as remembered on the same day; skip if it is already the next day; never take more than 4 puffs per day

    If you have previously used a beclomethasone-containing inhaler from a different manufacturer, ask your prescriber about the effective dose. Trimbow’s extrafine formulation may deliver equivalent clinical effect at a lower stated dose than some other BDP-containing products due to improved small airway deposition.

    Where Trimbow Fits in the U.S. Asthma Treatment Landscape

    Trimbow is the first single-inhaler ICS/LABA/LAMA approved for asthma in the United States. There are existing single-inhaler triple combinations approved for COPD, including Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) and Trelegy Ellipta (fluticasone/umeclidinium/vilanterol), but Trimbow is the first such combination with an asthma-specific approval in the U.S.

    Adding a LAMA to ICS/LABA therapy in asthma is already supported by GINA guidelines and the American Thoracic Society/European Respiratory Society guidelines for patients with uncontrolled moderate to severe asthma. What Trimbow provides is the ability to implement this strategy in a single inhaler, which has meaningful practical implications for patients managing multiple devices.

    A note on biologic therapy for severe asthma For patients with severe, refractory asthma and elevated eosinophils or IgE, biologic therapies targeting the type 2 inflammatory pathway are an important consideration alongside or instead of triple inhaled therapy. These include dupilumab (Dupixent), mepolizumab (Nucala), benralizumab (Fasenra), omalizumab (Xolair), and others. These are injected subcutaneous therapies with their own clinical trial programs and indications. Whether triple inhaled therapy or biologic therapy is the appropriate next step for a given patient depends on asthma phenotype, eosinophil count, allergy status, exacerbation history, and other clinical factors best discussed with a pulmonologist or allergist. Trimbow and biologic therapy are not mutually exclusive; some patients may use both.

    For Patients: What to Discuss With Your Doctor

    If your asthma is still not controlled despite consistent use of a combination ICS/LABA inhaler, Trimbow may be worth discussing with your pulmonologist or allergist. The relevant questions are:

    • Does my current asthma control score indicate uncontrolled disease despite adherent dual therapy?
    • Have I had exacerbations requiring oral steroids or emergency care in the past year?
    • Is my pre-bronchodilator FEV1 below normal, suggesting persistent airflow limitation?
    • Do I have any contraindications to a LAMA (glaucoma, significant urinary retention, active narrow-angle glaucoma)?
    • Am I currently on a separate LAMA or LABA that would need to be discontinued before starting Trimbow?

    For general asthma management resources, the American Lung Association and the Asthma and Allergy Foundation of America (AAFA) maintain patient-facing guides on asthma treatment, inhaler technique, and finding specialist care. The GINA Pocket Guide for Patients provides evidence-based guidance on asthma management that patients can review with their healthcare providers.

    Sources

    FDA approval news: FDA Approves Trimbow (beclomethasone/formoterol/glycopyrrolate) Inhaler for the Maintenance Treatment of Asthma. Drugs.com. May 14, 2026.

    Trimbow prescribing information: Trimbow (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate) Prescribing Information. Chiesi USA. 2026.

    Drugs.com drug information: Trimbow: Uses, Dosage, Side Effects and Warnings. drugs.com.

    TRIMARAN and TRIGGER primary Lancet publication: Virchow JC et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. The Lancet. 2019;394(10210):1737-1749. doi:10.1016/S0140-6736(19)32028-9.

    TRIMARAN trial registration: NCT02676076. ClinicalTrials.gov.

    TRIGGER trial registration: NCT02676089. ClinicalTrials.gov.

    Remission-on-treatment analysis: Post-hoc analysis of TRIMARAN and TRIGGER: achieving asthma remission with BDP/FF/GB. Journal of Allergy and Clinical Immunology. 2025.

    Subgroup determinants analysis: Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER. Respiratory Research. 2020. PMC7597025.

    Triple therapy review (extrafine formulation): Ridolo E et al. Extrafine formulation of beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide in the treatment of asthma: a review. Therapeutic Advances in Respiratory Disease. 2025.

    Small airways disease in asthma: Small Airways Disease in Asthma. PMC6560600.

    LABA FDA safety communication: FDA Drug Safety Communication: New safety requirements for long-acting inhaled asthma medications (LABAs). FDA.gov.

    NHLBI asthma overview: Asthma. National Heart, Lung, and Blood Institute.

    GINA guidelines: Global Initiative for Asthma (GINA) Reports. ginasthma.org.

    Beclomethasone dipropionate: Beclomethasone Dipropionate. StatPearls. NCBI.

    Formoterol fumarate: Formoterol Fumarate. StatPearls. NCBI.

    Glycopyrrolate/glycopyrronium: Glycopyrrolate. StatPearls. NCBI.

    ACQ-7 instrument: Asthma Control Questionnaire validation. PMC4799806.

    Patient resources: American Lung Association | Asthma and Allergy Foundation of America | GINA Guidelines

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Asthma management decisions, including changes to inhaler therapy, should be made in consultation with a qualified pulmonologist, allergist, or primary care provider familiar with your individual asthma history and current treatment.
  • Prolia Costs $2,500 a Dose. There Are Now 19 Biosimilar Competitors. Here’s What That Means for Patients.

    Prolia Costs $2,500 a Dose. There Are Now 19 Biosimilar Competitors. Here’s What That Means for Patients.

    📌 The essentials On March 30, 2026, Teva Pharmaceutical received FDA approval for PONLIMSI (denosumab-adet), a biosimilar to Prolia (denosumab, Amgen) for all five of Prolia’s approved indications. Commercial launch expected Q3 2026. This is the 19th FDA-approved denosumab biosimilar, not the first. Several have already launched commercially in the United States with modest savings of approximately 5 to 15% below Prolia’s list price. Critical distinction for patients: PONLIMSI is approved as a biosimilar but does NOT have interchangeable designation. Only Jubbonti (Sandoz) has interchangeable status for Prolia, meaning only Jubbonti can be substituted by a pharmacist without calling your prescriber. Simultaneously, Teva announced that the FDA and EMA have both accepted regulatory filings for its proposed omalizumab (Xolair) biosimilar. This is not an approval; it is the start of review. A Prolia discontinuation warning: do not stop denosumab abruptly for any reason, including a transition to a biosimilar. Rebound vertebral fractures are a documented serious risk. Any transition must be clinician-guided.

    Osteoporosis affects an estimated 200 million people globally and is responsible for approximately 9 million fractures per year worldwide. In the United States, about 10 million adults have osteoporosis and another 44 million have low bone density, putting them at elevated fracture risk. Hip fractures in older adults carry a one-year mortality rate of up to 36%, a statistic that makes bone health a genuine life-or-death clinical priority, not a cosmetic concern.

    Denosumab (Prolia, Amgen) is one of the most effective medications available for high-risk osteoporosis. It reduces vertebral fracture risk by up to 68%, hip fractures by 40%, and nonvertebral fractures by 20% in clinical trials. It is also, without insurance, a $2,506 injection administered twice a year, making it inaccessible or unaffordable for many of the patients who need it most.

    On March 30, 2026, Teva Pharmaceutical received FDA approval for PONLIMSI (denosumab-adet), a biosimilar to Prolia, and simultaneously announced that regulatory agencies in both the U.S. and Europe have accepted filings for its proposed biosimilar to Xolair (omalizumab), a biologic used in severe asthma, nasal polyps, and IgE-mediated food allergy. These are meaningful regulatory events, but they exist in a context that the original announcement does not capture: the denosumab biosimilar market is now crowded, savings to patients have been disappointingly modest so far, and understanding the difference between a biosimilar and an interchangeable biosimilar has real implications for whether your pharmacist can make the switch without calling your doctor.

    What Denosumab Does and Why It Is So Expensive

    Denosumab is a fully human monoclonal antibody that works by inhibiting RANKL, receptor activator of nuclear factor kappa-B ligand, a protein essential for the formation, function, and survival of osteoclasts, the cells responsible for breaking down bone. By blocking RANKL, denosumab suppresses bone resorption, which allows bone mineral density to increase and fracture risk to fall.

    Amgen markets denosumab under two brand names: Prolia (60 mg subcutaneous injection every 6 months) for osteoporosis and bone loss from hormonal cancer therapies, and Xgeva (120 mg every 4 weeks) for preventing skeletal-related events in patients with bone metastases and giant cell tumors. The two products use the same molecule but are approved for different indications at different doses.

    The $2,500+ price per dose reflects the cost of biologic drug manufacturing. Denosumab is produced in living cells using complex, expensive processes, not synthesized chemically like a small molecule tablet. Amgen has generated approximately $2.9 billion annually from Prolia alone. Despite recent patent expirations in the U.S. and Europe opening the door to biosimilar competition, the denosumab market has yet to see the dramatic price reductions that biosimilar proponents hoped for.

    A critical clinical nuance: the rebound fracture risk on discontinuation Denosumab has a well-documented risk of rebound vertebral fractures when treatment is stopped abruptly. Because denosumab’s anti-resorptive effect reverses quickly after the drug clears the system, faster than bisphosphonates which accumulate in bone tissue, stopping denosumab without transitioning to another therapy can produce a rapid spike in bone turnover that significantly increases fracture risk in the first 12 to 24 months after discontinuation. Multiple cases of simultaneous vertebral fractures following denosumab discontinuation have been reported in the literature. Current guidelines recommend that patients stopping denosumab for any reason, including switching to a biosimilar if the transition is not managed carefully, receive bridging therapy with a bisphosphonate. This is not a biosimilar-specific concern, but it is relevant for any patient or prescriber navigating a formulary switch or change in product.

    PONLIMSI: What the Approval Is Based On

    PONLIMSI (denosumab-adet) received FDA approval on March 30, 2026, based on a totality of evidence demonstrating comparable efficacy, safety, and immunogenicity to Prolia. This evidence includes data from a randomized, double-blind Phase 3 clinical trial (NCT04729621) enrolling 332 women with postmenopausal osteoporosis, comparing denosumab-adet directly against Prolia across these endpoints.

    PONLIMSI is approved for all five indications of the reference product Prolia:

    IndicationPatient Population
    Postmenopausal osteoporosisWomen at high risk for fracture, including history of fracture or multiple risk factors; or failed or intolerant to other osteoporosis therapy
    Male osteoporosisMen at high risk for fracture
    Glucocorticoid-induced osteoporosisMen and women on long-term corticosteroid therapy at high risk for fracture
    Prostate cancer bone lossMen at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
    Breast cancer bone lossWomen at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer

    The EMA granted marketing authorization for PONLIMSI in Europe in November 2025, meaning the drug had already been approved in the EU before its U.S. clearance. Teva has indicated a commercial launch in the United States is expected in Q3 2026.

    The Critical Distinction: Biosimilar vs. Interchangeable and Why It Matters for Patients

    This is the most practically important piece of information in this post, and it was absent from the original coverage of PONLIMSI’s approval.

    In the United States, there are two categories of FDA-approved biosimilars: biosimilar and interchangeable biosimilar. The difference matters at the pharmacy counter.

    BiosimilarInterchangeable Biosimilar
    FDA standardHighly similar to reference product; no clinically meaningful differences in safety, purity, potencySame as biosimilar PLUS: can be substituted without the prescriber’s involvement
    Pharmacy substitutionCannot be substituted automatically; requires prescriber authorization or new prescription in most statesCan be substituted by pharmacist without calling the prescriber (subject to state pharmacy laws)
    Benefit to payer and patientMay require step therapy or prior authorization to access lower costFormulary substitution can happen more easily, driving faster cost competition
    PONLIMSI statusBiosimilar only, NOT interchangeable (as of approval)Jubbonti (Sandoz) has interchangeable designation
    Real-world implicationPrescriber or insurer action typically neededPharmacist can swap without a call to the prescriber

    Teva’s announcement did not mention an interchangeability designation for PONLIMSI. This means that in most U.S. states, a pharmacist cannot automatically substitute PONLIMSI for Prolia based on a prescription for denosumab. A clinician or insurer action is typically required. Patients who want to access the biosimilar version may need to ask their provider to write a new prescription specifically for PONLIMSI, or navigate a formulary preference process through their insurer.

    The Denosumab Biosimilar Landscape: 19 Approvals, Modest Savings

    PONLIMSI is not entering an empty market. By the time it launches in Q3 2026, it will be one of at least 19 FDA-approved denosumab biosimilars. Eighteen were approved by the end of December 2025, with PONLIMSI the first addition in 2026. Several have already launched commercially in the United States.

    BiosimilarCompanyFDA StatusNotes
    Jubbonti / WyostSandozApproved March 2024; launched June 2025First to market; interchangeable designation; 14.5% below Prolia WAC
    Osenvelt / StobocloCelltrionLaunched July 20255 to 10% discount range reported
    Jubereq / OsvyrtiAccord BioPharmaLaunched October 2025Competitive pricing
    Enoby / XtrenboGedeon Richter / HikmaApproved; not yet launched—
    Bilprevda / BildyosHenlius / OrganonApproved; not yet launched—
    PONLIMSITevaApproved March 2026; Q3 2026 launch expectedNo interchangeability designation announced

    The savings picture has been a disappointment relative to earlier expectations. Sandoz’s Jubbonti, the first approved interchangeable denosumab biosimilar, launched in June 2025 at a list price approximately 14.5% below Prolia’s wholesale acquisition cost. Celltrion’s biosimilars entered at an estimated 5 to 10% discount. A published budget impact model in the Journal of Medical Economics projected savings of $0.59 per member per month for health plans at medium conversion rates over five years, meaningful at scale, but not the 50 to 80% price reductions that biosimilar competition drove in markets like Europe.

    Why are U.S. denosumab biosimilar savings so modest compared to Europe? In the UK, biosimilar adoption within the first year of launch routinely exceeds 90% of market share, driven by NHS tender-based procurement and institutional formulary switches. British rheumatologist Dr. Muhammad Nisar noted to Medscape that clinicians feel very comfortable with denosumab biosimilars, with great belief in their efficacy and safety. In the U.S., the market structure is fundamentally different. Amgen has kept Prolia competitively priced through rebates to pharmacy benefit managers (PBMs) and insurers. The net price paid by many payers may already be below the biosimilar list price after rebates. This perverse dynamic, in which originator rebates can make a brand-name drug cheaper to a payer than the biosimilar list price, is a structural feature of the U.S. drug market that dampens biosimilar adoption and competition. The interchangeability designation matters here too. Only Sandoz’s Jubbonti has interchangeable status for Prolia, allowing direct pharmacy substitution. The other approved denosumab biosimilars, including PONLIMSI, require prescriber action or payer-directed formulary changes to reach patients, slowing the pace of market conversion.

    The Xolair Biosimilar Filing: A Different Market, A Different Opportunity

    Teva’s simultaneous announcement that both the FDA and EMA have accepted filings for its proposed biosimilar to Xolair (omalizumab, Genentech/Novartis) is a separate and strategically distinct event from the PONLIMSI approval.

    What omalizumab is and who uses it

    Omalizumab (Xolair) is a monoclonal antibody that works by binding to free IgE, immunoglobulin E, the antibody class central to allergic responses, and blocking its interaction with IgE receptors on mast cells and basophils. By reducing free IgE levels, omalizumab prevents the downstream allergic cascade that produces symptoms in atopic disease.

    Xolair is approved in the U.S. for: moderate-to-severe persistent allergic asthma inadequately controlled by inhaled corticosteroids in patients 6 and older whose asthma is related to a perennial allergen; chronic rhinosinusitis with nasal polyps in adults; chronic spontaneous urticaria in patients whose symptoms are inadequately controlled by antihistamines; and IgE-mediated food allergies in patients 1 year and older. That food allergy indication, the most recent addition, significantly expanded the patient population that might use omalizumab.

    The market context

    Global omalizumab sales are estimated at $3.5 to $3.7 billion annually, making this a commercially meaningful biosimilar target. Regulatory filing acceptance by both FDA and EMA simultaneously means Teva’s submission was complete enough for substantive review. This is not an approval; it is the beginning of the regulatory review process. The FDA’s standard review clock for biosimilar applications is 12 months from acceptance.

    The omalizumab biosimilar market is at an earlier stage than denosumab. The omalizumab biosimilar landscape will be watched carefully by allergists, pulmonologists, and patients with severe allergic disease who currently pay thousands of dollars per year for brand-name Xolair, a cost that is a meaningful access barrier for many.

    What This Means in Practice: Guidance for Patients

    If you are currently on Prolia or another denosumab product

    Do not stop denosumab without a medical plan for what comes next. The rebound fracture risk on discontinuation is real and serious. Any transition to a biosimilar should be clinician-guided, maintaining the same dosing schedule (every 6 months for Prolia indications) and likely incorporating a bisphosphonate bridge if you stop denosumab for any reason.

    If cost is a barrier to accessing denosumab, ask your prescriber or pharmacist specifically about available biosimilar options. If your insurer’s formulary includes an interchangeable denosumab biosimilar like Jubbonti, your pharmacist may be able to substitute automatically. For non-interchangeable biosimilars like PONLIMSI, a prescriber action is required. Medicare Part B, through which administered biologics are often covered, has specific biosimilar substitution rules worth understanding with your provider.

    If you are on Xolair for allergic asthma, nasal polyps, urticaria, or food allergy

    A biosimilar is not yet available. Teva’s application is under review, and even after approval, launch timing will depend on regulatory processes and commercial decisions. Continue your current treatment as prescribed. Monitor your insurer’s formulary for updates in 2026 and 2027.

    The Gap Between Biosimilar Approval and Patient Savings

    The denosumab biosimilar story is instructive for understanding how U.S. drug pricing actually works and why regulatory approval of a biosimilar does not automatically translate to patient savings.

    When Prolia’s key patents began expiring, the expectation was that biosimilar competition would drive meaningful price reductions, as it has in Europe. Instead, 19 FDA approvals later, the most aggressive biosimilar discount achieved is about 14.5% below Prolia’s list price. The originator still commands most of the market. The structural reasons are complex: Amgen’s rebate practices, the lack of interchangeability designation for most competitors, the physician-administered nature of the injection (which keeps it under Part B rather than Part D, with different substitution rules), and the clinical hesitancy around switching patients who have been stable on a therapy that must not be interrupted without a plan.

    Flanigan et al. noted in their 2025 Journal of Medical Economics budget impact analysis that even a small discount of 5% for a biosimilar referencing Xgeva and Prolia could represent millions of dollars in savings for a health plan, with the potential for reinvestment to further expand access. Those savings are real at scale even when they feel modest at the individual patient level.

    None of this means biosimilar approvals like PONLIMSI are without value. For payers, even modest per-dose discounts multiply across large patient populations. For patients in countries with less fragmented pricing structures, competitive biosimilar availability is genuinely transformative. And building a competitive biosimilar market, however slowly, creates the foundation for the price competition that patients deserve.

    The omalizumab filing, if it leads to approval and launch, enters a somewhat less saturated biosimilar market. The recent addition of the food allergy indication has expanded the potential patient population substantially. That approval, if and when it comes, may be a more commercially differentiated moment than PONLIMSI in the already crowded denosumab space.

    For related coverage of how access and affordability are shaping the drug landscape in 2026, see our post on FDA approval of the first generic dapagliflozin, where a similar story of high list prices, biosimilar or generic entry, and the gap between approval and real-world savings is unfolding in the type 2 diabetes space.

    Sources

    Teva press release: Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair (omalizumab). March 30, 2026. ir.tevapharm.com.

    Clinical Advisor coverage: FDA Approves Teva’s Prolia Biosimilar Ponlimsi, Accepts Xolair Biosimilar for Review. clinicaladvisor.com. April 2026.

    Drug Topics: FDA Approves Denosumab-Adet as Biosimilar to Prolia. drugtopics.com. March 2026.

    Center for Biosimilars: FDA Approves Teva Biosimilar for Denosumab in Osteoporosis. centerforbiosimilars.com. March 2026.

    GaBI Online: FDA approves denosumab biosimilar Ponlimsi. gabionline.net. April 2026.

    Medscape: Two More Denosumab Biosimilars Approved in the US. medscape.com. October 2025.

    Managed Healthcare Executive: Biosimilar denosumab could save $0.59 per member per month. managedhealthcareexecutive.com. February 2026.

    Journal of Medical Economics budget impact: Flanigan J, Chaplin S, et al. A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology population. J Med Econ. 2025;28(1):2027-2038. doi:10.1080/13696998.2025.2027-2038.

    PONLIMSI Phase 3 trial: NCT04729621. ClinicalTrials.gov.

    GoodRx pricing: How Much Is Prolia Without Insurance? goodrx.com.

    Rebound fracture risk: Rebound vertebral fractures after denosumab discontinuation. PMC6683162.

    Denosumab mechanism: Denosumab. StatPearls. NCBI.

    RANKL biology: RANKL in bone biology. PMC3386061.

    Hip fracture mortality: Hip fracture 1-year mortality. PMC6530614.

    FDA biosimilars explained: Biosimilar and Interchangeable Products. FDA.gov.

    FDA approved biosimilar products: FDA-Approved Biosimilar Products. FDA.gov.

    Prolia FDA approval: FDA approves denosumab for osteoporosis. FDA.gov.

    Xgeva FDA approval: FDA approves denosumab (Xgeva). FDA.gov.

    Xolair FDA approval: FDA approves omalizumab for allergic asthma. FDA.gov.

    IgE biology: IgE in allergy. StatPearls. NCBI.

    PBM market structure: Pharmacy Benefit Managers. PMC7748166.

    Bisphosphonates: Bisphosphonates. StatPearls. NCBI.

    Patient resources: Bone Health and Osteoporosis Foundation | FDA Biosimilar Products List | GoodRx Prolia pricing

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about denosumab therapy, including switching between reference products and biosimilars, should be made in consultation with a qualified prescriber familiar with the patient’s bone health history and fracture risk. Never discontinue denosumab without medical guidance.